These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9624253)

  • 1. In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl-beta-cyclodextrin.
    Grosse PY; Bressolle F; Pinguet F
    Eur J Cancer; 1998 Jan; 34(1):168-74. PubMed ID: 9624253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methyl-beta-cyclodextrin in HL-60 parental and multidrug-resistant cancer cell lines: effect on the cytotoxic activity and intracellular accumulation of doxorubicin.
    Grosse PY; Bressolle F; Pinguet F
    Cancer Chemother Pharmacol; 1997; 40(6):489-94. PubMed ID: 9332463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproliferative effect of methyl-beta-cyclodextrin in vitro and in human tumour xenografted athymic nude mice.
    Grosse PY; Bressolle F; Pinguet F
    Br J Cancer; 1998 Nov; 78(9):1165-9. PubMed ID: 9820174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor cell membrane as a potential target for methyl-beta-cyclodextrin.
    Grosse PY; Bressolle F; Vago P; Simony-Lafontaine J; Radal M; Pinguet F
    Anticancer Res; 1998; 18(1A):379-84. PubMed ID: 9568106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methyl-beta-cyclodextrin and doxorubicin pharmacokinetics and tissue concentrations following bolus injection of these drugs alone or together in the rabbit.
    Grosse PY; Bressolle F; Rouanet P; Joulia JM; Pinguet F
    Int J Pharm; 1999 Apr; 180(2):215-23. PubMed ID: 10370192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel in doxorubicin-resistant metastatic breast cancer patients.
    Anand A; Anand A
    J Natl Cancer Inst; 1995 Nov; 87(21):1642. PubMed ID: 7563210
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines.
    Ikubo S; Takigawa N; Ueoka H; Kiura K; Tabata M; Shibayama T; Chikamori M; Aoe K; Matsushita A; Harada M
    Anticancer Res; 1999; 19(5B):3985-8. PubMed ID: 10628341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers.
    Zoli W; Flamigni A; Frassineti GL; Bajorko P; De Paola F; Milandri C; Amadori D; Gasperi-Campani A
    Breast Cancer Res Treat; 1995 Apr; 34(1):63-9. PubMed ID: 7749161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Chan S
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
    Aapro M
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):7-11. PubMed ID: 9865705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrochemical monitoring of anticancer compounds on the human ovarian carcinoma cell line A2780 and its adriamycin- and Cisplatin-resistant variants.
    Woolley DE; Tetlow LC; Adlam DJ; Gearey D; Eden RD; Ward TH; Allen TD
    Exp Cell Res; 2002 Feb; 273(1):65-72. PubMed ID: 11795947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel and docetaxel in breast and ovarian cancer.
    Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel in breast cancer and a rationale for combination therapy.
    Hortobágyi G
    Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):11-5. PubMed ID: 9213321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
    Ojima I; Slater JC; Michaud E; Kuduk SD; Bounaud PY; Vrignaud P; Bissery MC; Veith JM; Pera P; Bernacki RJ
    J Med Chem; 1996 Sep; 39(20):3889-96. PubMed ID: 8831755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel: an update of its use in advanced breast cancer.
    Figgitt DP; Wiseman LR
    Drugs; 2000 Mar; 59(3):621-51. PubMed ID: 10776837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
    Ravdin PM
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds.
    Kars MD; Iseri OD; Gündüz U; Ural AU; Arpaci F; Molnár J
    Anticancer Res; 2006; 26(6B):4559-68. PubMed ID: 17201178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel in anthracycline-resistant metastatic breast cancer.
    Hui YF; Ignoffo RJ
    Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel enhances the cytotoxicity of anthracyclines by increasing intracellular drug accumulation.
    Egawa T; Kubota T; Suto A; Otani Y; Furukawa T; Watanabe M; Kumai K; Kitajima M
    Oncol Rep; 2002; 9(4):777-81. PubMed ID: 12066208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
    Ravdin PM; Burris HA; Cook G; Eisenberg P; Kane M; Bierman WA; Mortimer J; Genevois E; Bellet RE
    J Clin Oncol; 1995 Dec; 13(12):2879-85. PubMed ID: 8523050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.